4 Ways That AI And Point-Of-Care Diagnostics Are Redefining Clinical Trial Design And Operations
By Partha Anbil and Deepak Manjrekar
AI and ML are fundamentally shifting how, where, and when diagnostics are performed. Once confined to centralized laboratories, diagnostic testing is rapidly decentralizing. The COVID-19 pandemic compressed a decade of diagnostic innovation into just two years. And now, in 2026, point-of-care testing (POCT) has evolved from simple lateral flow assays into sophisticated, software-defined diagnostic platforms that integrate advanced signal processing, complex image analysis, and privacy-preserving federated learning architectures.
For clinical development and operations professionals, understanding the intersection of AI and POCT will alter how they design and execute clinical trials. AI-enhanced POCT directly affects enrollment speed, participant safety, data accuracy, and patient burden, and clinical operations professionals who know how to harness these advancements will be best suited to design and execute the next generation of clinical trials.
Accelerating Trial Execution and Enrollment Speed
A primary challenge in clinical research has always been patient recruitment and enrollment. Historically, identifying eligible patients, particularly for complex trials with stringent inclusion and exclusion criteria, required manual chart reviews and centralized laboratory testing, which often delayed screening and increased screen failure rates.
Integrating AI-powered POCT significantly accelerates this process. By utilizing rapid diagnostic tests embedded with AI algorithms at the point of care, clinical sites can quickly and accurately screen patients. For instance, AI-assisted point-of-care imaging and molecular diagnostics can deliver laboratory-grade quantitative detection in mere minutes.1 This capability allows coordinators to determine eligibility during a patient’s initial visit. In acute care trials, such as those for sepsis or infectious diseases, where waiting days for a standard blood culture could delay lifesaving treatment, rapid POC diagnostics can identify pathogens and susceptibility within an hour, enabling faster inclusion in the appropriate study arm.2
Furthermore, AI algorithms can process unstructured EHR data alongside real-time POC test results to automate patient-to-trial matching. Studies have demonstrated that joint human and AI prescreening can raise chart-level accuracy and significantly reduce the time required for manual matching.3
What Clinical Operations Should Do: ClinOps teams should integrate AI-enhanced POC testing directly into study protocols’ screening procedures. In doing so, they can streamline the informed consent process, quickly identify target populations, and reduce patient loss to key analysis sets. Protocols designed to leverage these rapid results can support immediate randomization, thereby shortening overall trial timelines.
Enhancing Patient Safety and Real-Time Monitoring
Patient safety remains paramount in clinical development. Traditional safety monitoring often relies on intermittent site visits, which may miss critical adverse events that occur between appointments. AI-enhanced POCT, particularly through wearable sensors, offers a continuous real-time safety net.
Wearable technologies, such as continuous glucose monitors or biosensor patches, collect vast amounts of physiological data continuously.4 When paired with AI and ML, these devices collect data and then analyze it for patterns and anomalies. For example, AI can detect arrhythmias from wearable ECG monitors or predict potential adverse events by identifying subtle physiological changes.1,4 This real-time monitoring allows sponsors and clinicians to quickly identify negative trends, prompting swift modifications to therapy or study protocols, thereby mitigating risks before they escalate into serious adverse events.
What Clinical Operations Should Do: ClinOps teams must evaluate and incorporate validated AI-powered wearable sensors in Phase 2-4 trials. It is crucial to establish robust data management pipelines that can manage continuous data streams and alert clinical investigators to safety signals in real time. Additionally, teams must ensure these devices comply with regulatory standards (e.g., FDA, CE mark) to maintain data integrity and patient safety.4
Improving Accuracy and Data Harmonization
Traditional clinical trials often suffer from subjective data interpretation and patient recall bias, particularly when relying on self-reported outcomes or manual readings of diagnostic tests. AI can mitigate these issues by standardizing interpretation and providing objective quantitative data.
For example, traditional lateral flow assays rely on visual inspection, which can be ambiguous. AI-powered smartphone applications use complex colorimetric segmentation to quantify biomarker levels directly from images, achieving accuracies exceeding 98% and eliminating subjective human error.5 Moreover, AI ensures that the vast amounts of data generated by decentralized POC devices are harmonized and integrated seamlessly into EDC systems.
What Clinical Operations Should Do: Clinical data managers and operations leads must prioritize clinical data harmonization. As trials utilize diverse POC devices across global sites, leaders must establish standardized data formats and interoperability with existing EDC systems. Operations should adopt AI tools that not only collect data but also automatically clean and structure it, ensuring high-quality, reliable data sets for regulatory submission.
Reducing Patient Burden Through Decentralized Trials
The traditional clinical trial model places a heavy travel burden on patients, which can contribute to high dropout rates. AI-enhanced POCT is the technological backbone enabling the shift toward DCTs.
By deploying diagnostics to the patient’s home or local community clinic, the geographic and logistical barriers to participation are dismantled. Wearables and smartphone-based diagnostic apps allow patients to participate actively in trials without disrupting their daily lives.4 AI algorithms can also customize engagement, using reinforcement learning to understand a participant’s habits and tailor reminders, which reduces survey fatigue and improves adherence.6
What Clinical Operations Should Do: To improve retention and expand access to diverse populations, ClinOps should design hybrid trials or DCTs around AI-enabled POC technologies. Operations teams must ensure that devices provided to patients are user-friendly and require minimal technical expertise. Furthermore, they should leverage federated learning architectures to ensure that data processed locally on patient devices remains secure and compliant with privacy regulations like HIPAA and GDPR.5
Redefining Trial Design: Adaptive And Biomarker-Driven Protocols
AI and POCT are changing how trials are run and designed. Biomarker-driven enrichment strategies, supported by rapid POC molecular diagnostics, ensure that enrolled patients are biologically positioned to respond to the intervention.
Moreover, AI facilitates adaptive trial designs. By continuously analyzing incoming POC data, AI models can inform interim decisions—such as modifying sample sizes, dropping ineffective dose arms, or refining inclusion criteria—without waiting for the trial’s conclusion.7 This flexibility improves trial success rates while reducing time and cost.
What Clinical Operations Should Do: Protocol designers must move away from rigid, static designs and embrace living protocols. ClinOps should collaborate with statisticians to implement Bayesian adaptive designs, ensuring that the AI models used for interim decision-making are transparent, prespecified, and aligned with recent FDA guidance.7
Conclusion
For clinical development and operations professionals, this convergence of AI and POC diagnostics offers an opportunity to execute trials faster, monitor safety more accurately, and reduce patient burden. By proactively embedding AI-enhanced POCT into trial designs, prioritizing data harmonization, and embracing decentralized models, ClinOps and supporting teams can bridge the translational gap and accelerate the delivery of life-changing therapies to patients.
References:
- DelveInsight. “The Rise of AI-Powered Point-of-Care Diagnostics: Transforming Real-Time Patient Care.” https://www.delveinsight.com/blog/ai-powered-point-of-care-diagnostics
- Fortrea. “Rapid diagnostic advantages in clinical research.” https://www.fortrea.com/insights/rapid-diagnostic-advantages-clinical-research
- ASCO Daily News. “Joint Human and AI Teams Bring Real-Time Trial Matching to the Point of Care.” https://dailynews.ascopubs.org/do/joint-human-and-ai-teams-bring-real-time-trial-matching-point-care
- Quanticate. “The Use of Wearables in Clinical Trials.” https://www.quanticate.com/blog/wearables-in-clinical-trials
- Nature Communications. “Machine learning in point-of-care testing: innovations, challenges, and opportunities.” https://www.nature.com/articles/s41467-025-58527-6
- JACC: Advances. “The Introduction of AI Into Decentralized Clinical Trials.” https://pmc.ncbi.nlm.nih.gov/articles/PMC11277430/
- Drug Discovery News. “AI in clinical trials: Patient selection, adaptive design, and the translational gap.” https://www.drugdiscoverynews.com/ai-in-clinical-trials-patient-selection-adaptive-design-and-the-translational-gap-17368
Authors’ notes: The views expressed in the article are those of the authors and not of the organizations they represent.
About The Authors:
Partha Anbil is at the intersection of the life sciences industry and management consulting. He has 30+ years of experience in life sciences and is a life sciences industry advisor at MIT, his alma mater. He held senior leadership roles at WNS, IBM, Booz & Company, Symphony, IQVIA, KPMG Consulting, and PWC. Anbil has consulted with and counseled health and life sciences clients on structuring solutions to address strategic, operational, and organizational challenges. He is a diplomat/fellow at MIT CSAIL and a healthcare expert member of the World Economic Forum (WEF). He was a member of the invitation-only IBM Industry Academy, IBM's highest honor.
Deepak Manjrekar is a veteran data and AI leader with over three decades of experience driving business transformation through data. He leads his tema’s data and AI growth strategy, building on leadership roles at Mphasis and KPIT, where he successfully scaled high-growth data businesses.